Hippocampus, Cortical Atrophy, Demyelination – micro stroke, small vessel ischemia, delayed P300 circuits, and hypometabolism.
The aging brain has increased frequency of amnestic and nonamnestic domains of lost memory. We evaluated the following domains in 230 subjects: amnestic single domain (1%); amnestic multi domain (20.8%); nonamnestic single domain (24.8%); nonamnestic multi domain (44.3%); and no signs of MCI (9.1%).
Subjects at greater risk for MCI progression to dementia are categorized as multi domain amnestic and nonamnestic. The regions of the brain most affected in memory loss begin with the parietal lobe, followed by the temporal, frontal, and occipital lobes respectively. Most patients are also at risk for increased atrophy of the hippocampus and/or cortex with increased demyelination, micro stroke or other micro ischemic events, and electrophysiological slowing, particularly the separation from thought to action (TOVA/P300).
P300 latencies greater than 330 are associated with diseases such as hypothyroidism, male and female menopause, growth hormone deficiency, obesity, dementia, Parkinson’s, and Alzheimer’s. These changes are antecedents to PET hypometabolism and can be detected by cost effective procedures such as MCI domain checklists, EPs, CNSM, WMS, MMSE, P300, and TOVA. MCI progression to dementia from one to thirty years is dependent on levels of atrophy, ischemic changes, circuit delays, and other related medical and endocrine problems.
Eric R. Braverman, M.D.
Dr. Braverman is a Summa Cum Laude and Phi Beta Kappa graduate of Brandeis University and NYU Medical School, did brain research at Harvard Medical School, and trained at an affiliate of Yale Medical School. He is acknowledged worldwide as an expert in brain-based diagnosis and treatment, and he lectures to and trains doctors in anti-aging medicine.